Buszman Pawel E, Buszman Piotr P, Kiesz R Stefan, Bochenek Andrzej, Trela Blazej, Konkolewska Magda, Wallace-Bradley David, Wilczyński Mirosław, Banasiewicz-Szkróbka Iwona, Peszek-Przybyla Ewa, Krol Marek, Kondys Marek, Milewski Krzysztof, Wiernek Szymon, Debiński Marcin, Zurakowski Aleksander, Martin Jack L, Tendera Michał
Medical University of Silesia, Katowice, Ziolowa 45/47 Street, Poland.
J Am Coll Cardiol. 2009 Oct 13;54(16):1500-11. doi: 10.1016/j.jacc.2009.07.007. Epub 2009 Aug 21.
The aim of the study was to evaluate early and late outcomes after percutaneous coronary intervention (PCI) of unprotected left main coronary artery disease (ULMCA) and to compare bare-metal stent (BMS) and drug-eluting stent (DES) subgroups.
PCI is an increasingly utilized method of revascularization in patients with ULMCA.
This multicenter prospective registry included 252 patients after ULMCA stenting enrolled between March 1997 and February 2008. Non-ST-segment elevation acute coronary syndrome was diagnosed in 58% of patients; ST-segment elevation myocardial infarction cases were excluded. Drug-eluting stents were implanted in 36.2% of patients.
Major adverse cardiovascular and cerebral events (MACCE) occurred in 12 (4.8%) patients during the 30-day period, which included 4 (1.5%) deaths. After 12 months there were 17 (12.1%) angiographically confirmed cases of restenosis. During long-term follow-up (1 to 11 years, mean 3.8 years) there were 64 (25.4%) MACCE and 35 (13.9%) deaths. The 5- and 10-year survival rates were 78.1% and 68.9%, respectively. Despite differences in demographical and clinical data in favor of BMS patients, unmatched analysis showed a significantly lower MACCE rate in DES patients (25.9% vs. 14.9%, p = 0.039). This difference was strengthened after propensity score matching. The DES lowered both mortality and MACCE for distal ULMCA lesions when compared with BMS. Ejection fraction <50% was the only independent risk factor influencing long-term survival.
Stenting of ULMCA is feasible and offers good long-term outcome. Implantation of DES for ULMCA decreased the risk of long-term MACCE, and particularly improved survival in patients with distal ULMCA disease.
本研究旨在评估无保护左主干冠状动脉疾病(ULMCA)经皮冠状动脉介入治疗(PCI)后的早期和晚期结果,并比较裸金属支架(BMS)和药物洗脱支架(DES)亚组。
PCI在ULMCA患者中越来越多地被用作血管重建方法。
本多中心前瞻性注册研究纳入了1997年3月至2008年2月期间接受ULMCA支架置入术的252例患者。58%的患者被诊断为非ST段抬高型急性冠状动脉综合征;ST段抬高型心肌梗死病例被排除。36.2%的患者植入了药物洗脱支架。
30天内12例(4.8%)患者发生主要不良心血管和脑血管事件(MACCE),其中包括4例(1.5%)死亡。12个月后,有17例(12.1%)经血管造影证实的再狭窄病例。在长期随访(1至11年,平均3.8年)期间,有64例(25.4%)发生MACCE,35例(13.9%)死亡。5年和10年生存率分别为78.1%和68.9%。尽管在人口统计学和临床数据方面BMS患者具有优势,但未匹配分析显示DES患者的MACCE发生率显著较低(25.9%对14.9%,p = 0.039)。倾向评分匹配后,这种差异更加明显。与BMS相比,DES降低了ULMCA远端病变患者的死亡率和MACCE。射血分数<50%是影响长期生存的唯一独立危险因素。
ULMCA支架置入术是可行的,且具有良好的长期结果。植入DES可降低ULMCA患者长期MACCE的风险,尤其改善了ULMCA远端病变患者的生存率。